Our team
Board of Directors
Luis Sánchez-Lafuente
Chairman
Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA
Carles Domènech
Executive chairman
Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL
José Manuel Valadés
General secretary
Lawyer, partner and founder of the law firm Alliant Abogados
Miquel Àngel Bonachera
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.
BSc/MSc in biochemistry and MBA.
Sergi Audivert
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in food technology and MBA.
BSc/MSc in food technology and MBA.
Sara Secall
Operating Partner & Life Sciences Investment Director of Inveready Asset Management
German Cutillas
Venture Capital Partner at Fitalent (grup Everis)
Roger Piqué
Managing director and co-founder of Inveready Seed Capital SCR.
LATEST NEWS
28.12.2020
Press Release
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020
Press Release
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020
Press Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020
Press Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020
Press Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020
Press Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020
Press Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019
Press Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019
Press Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
